CYP2D6 Polymorphism
10
1
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
20%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Long-term Follow-up of Depressive Disorders in Psychiatric Care
The Impact of CYP2D6 Polymorphism on Tramadol Pharmacodynamics
Effects of Isotretinoin on CYP2D6 Activity
Effects of Retinoids on CYP2D6 Activity During Pregnancy
Biomarkers of P. Vivax Relapse
Precision Medicine Guided Treatment for Cancer Pain
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
Cytochrome P450's Pharmacogenomics in Chronic Pain Patients
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms